Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Paclitaxel 50Capecitabine 50Trastuzumab 38Fulvestrant 31pembrolizumab 27Cyclophosphamide 27Carboplatin 27Gemcitabine 23Letrozole 21palbociclib 19Docetaxel 19Lapatinib 18Bevacizumab 18exemestane 17eribulin 15Everolimus 14abemaciclib 13Vinorelbine 13Nivolumab 13Magnetic Resonance Spectroscopy 12Cisplatin 12Anastrozole 12trastuzumab deruxtecan 11Zoledronic Acid 11Doxorubicin 11Albumin-Bound Paclitaxel 11olaparib 10Tamoxifen 10Specimen Handling 10Radiotherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × devimistat × Breast × Clear all
NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Cornerstone Pharmaceuticals

Phase 2 Terminated
7 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡